Evolution of the Average Target: AstraZeneca PLC

Evolution of the Average Target - AstraZeneca PLC

Evolution of the Target Price: AstraZeneca PLC

Evolution of the Target Price - AstraZeneca PLC

Changes in Analyst Recommendations: AstraZeneca PLC

a18a7e0cac74e5bd68f727f5d8db27.PZaafidW4LIFPf9NzBlUP2OtfSBPhAFt8FcHYmb-GD0.b9H7Bh4DjtBTRIYdiTQ5ZyD-MkgYqWAKp24xURWYVn5l1_ATdDSWwGYFmA~20daefe9a5b1303065454d3192c26278
10-16 AstraZeneca PLC : Berenberg remains its Buy rating ZD
10-15 RBC Reaffirms AstraZeneca's Outperform Rating Ahead of Q3 Results MT
10-15 AstraZeneca PLC : UBS gives a Buy rating ZD
10-15 AstraZeneca PLC : Gets a Buy rating from RBC ZD
10-14 AstraZeneca PLC : Deutsche Bank reiterates its Neutral rating ZD
10-07 Berenberg Trims AstraZeneca PT, Affirms Outperform Rating MT
10-07 Deutsche Bank ups Glencore, BHP price targets AN
10-07 AstraZeneca PLC : Buy rating from Berenberg ZD
10-07 AstraZeneca PLC : Jefferies gives a Buy rating ZD
10-07 AstraZeneca PLC : Bernstein reaffirms its Buy rating ZD
10-06 Genmab in Good Health, Schneider Lacks Energy Zonebourse
10-06 BofA Forecasts 'In-line' Q3, Unchanged FY26 Outlook for AstraZeneca Amid Oncology Momentum MT
09-30 AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating ZD
09-29 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says MT
09-29 Stocks Defy the Pressure Zonebourse
09-29 AstraZeneca PLC : Jefferies keeps its Buy rating ZD
09-29 AstraZeneca PLC : RBC reaffirms its Buy rating ZD
09-29 AstraZeneca PLC : JP Morgan maintains a Buy rating ZD
09-29 AstraZeneca PLC : Deutsche Bank is Neutral ZD
09-18 Berenberg and Deutsche say buy Bytes Technology AN
09-16 AstraZeneca PLC : Gets a Buy rating from UBS ZD
09-16 Oddo BHF cuts Safestore to neutral, cuts target AN
09-16 AstraZeneca PLC : Buy rating from Jefferies ZD
09-16 AstraZeneca PLC : JP Morgan keeps its Buy rating ZD
09-16 AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+6.11%
+10.32%
-0.28%
-0.65%
+9.26%
-1.09%
+24.17%
-9%
+1.57%
Average +4.49%
Weighted average by Cap. +5.15%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
166.04USD
Average target price
210.50USD
Spread / Average Target
+26.78%
High Price Target
262.96USD
Spread / Highest target
+58.38%
Low Price Target
154.83USD
Spread / Lowest Target
-6.75%

Analyst Consensus Detail

Analyst consensus - AstraZeneca PLC

Consensus revision (last 18 months)

Consensus revision (last 18 months) - AstraZeneca PLC
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC